GlassScriptPhysician profile
Derek B Benz
NPI 1033703624
$4,325.72
in general payments reported to CMS, 2019-2025
27 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $450 · 2022: $407 · 2023: $865 · 2024: $2,462 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,292 · Travel and Lodging: $1,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,291.57 |
| Travel and Lodging | $1,177.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,399.31 | 2024 | Stratafix |
| Lilly USA, LLC | $457.79 | 2021-2024 | Mounjaro, Zepbound, Trulicity |
| Novo Nordisk INC | $328.75 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Depuy Synthes Sales INC. | $291.05 | 2024-2025 | |
| Daiichi Sankyo INC. | $225.55 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $161.97 | 2021-2024 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $149.67 | 2021-2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $134.65 | 2021-2024 | Trintellix |
| Ethicon US, LLC | $133.27 | 2024 | Dermabond Prineo, Stratafix, Monocryl |
| Glaxosmithkline, LLC. | $132.64 | 2022-2024 | Shingrix, Bexsero, Pediarix |
| Dexcom, INC. | $121.62 | 2021-2024 | Dexcom G6 Transmitter |
| Pfizer INC. | $121.10 | 2021-2024 | |
| Abbvie INC. | $111.54 | 2023-2024 | |
| Axsome Therapeutics, INC. | $78.00 | 2024 | Auvelity |
| Fisher & Paykel Healthcare INC | $75.96 | 2023 | Fisher & Paykel Healthcare |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $75.41 | 2022-2024 | Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $66.35 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $59.77 | 2023-2024 | Rexulti |
| Eisai INC. | $38.37 | 2023-2024 | |
| Lundbeck LLC | $29.01 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $29.01 | 2023-2024 | Vaxelis, Gardasil 9, Rotateq |
| Exact Sciences Corporation | $26.26 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $24.45 | 2024 | Voquezna |
| Astellas Pharma US INC | $17.10 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.20 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $12.64 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Benz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.